Health Care [ 4/12 ] | Pharmaceuticals [ 10/74 ]
NASDAQ | Common Stock
Clearside Biomedical, Inc., a biopharmaceutical company, focuses on the revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal space.
The company offers XIPERE, a triamcinolone acetonide injectable suspension for the treatment of macular edema associated with uveitis.
It also develops CLS-AX, an axitinib injectable suspension for suprachoroidal injection, which has completed Phase 2 clinical trial to treat wet AMD.
The company has a collaboration with bausch + lomb ireland limited, Arctic Vision (Hong Kong) Limited, REGENXBIO, Inc., BioCryst Pharmaceuticals, Inc., and Aura Biosciences, Inc. Clearside Biomedical, Inc. was incorporated in 2011 and is headquartered in Alpharetta, Georgia.
| Reported date | EPSChange YoY | EstimateSurprise |
|---|---|---|
| May 7, 25 | -0.11 Increased by +26.67% | -0.14 Increased by +21.43% |
| Mar 10, 25 | -0.10 Decreased by -25.00% | -0.10 Increased by +3.19% |
| Nov 12, 24 | -0.10 Increased by +33.33% | -0.12 Increased by +16.67% |
| Aug 12, 24 | -0.10 Increased by +33.33% | -0.13 Increased by +23.08% |
| May 9, 24 | -0.15 Increased by 0.00% | -0.14 Decreased by -7.14% |
| Mar 12, 24 | -0.08 Increased by +50.00% | -0.09 Increased by +11.11% |
| Nov 13, 23 | -0.15 Decreased by -15.38% | -0.15 |
| Aug 14, 23 | -0.15 Decreased by -15.38% | -0.14 Decreased by -7.14% |
| Fiscal ending date | RevenueChange YoY | IncomeChange YoY | ProfitChange YoY |
|---|---|---|---|
| Mar 31, 25 | 2.33 M Increased by +913.04% | -8.22 M Increased by +30.09% | Decreased by -352.92% Increased by +93.10% |
| Dec 31, 24 | 306.00 K Decreased by -95.18% | -7.31 M Decreased by -51.20% | Decreased by -2.39 K% Decreased by -3.04 K% |
| Sep 30, 24 | 1.04 M Increased by +20.84% | -7.69 M Increased by +17.04% | Decreased by -740.66% Increased by +31.35% |
| Jun 30, 24 | 90.00 K Decreased by -91.16% | -7.59 M Increased by +16.60% | Decreased by -8.44 K% Decreased by -843.30% |
| Mar 31, 24 | 230.00 K Increased by +5.65 K% | -11.76 M Decreased by -26.76% | Decreased by -5.11 K% Increased by +97.80% |
| Dec 31, 23 | 6.34 M Increased by +1.82 K% | -4.83 M Increased by +43.74% | Decreased by -76.15% Increased by +97.07% |
| Sep 30, 23 | 859.00 K Increased by +222.93% | -9.27 M Decreased by -18.40% | Decreased by -1.08 K% Increased by +63.34% |
| Jun 30, 23 | 1.02 M Increased by +165.10% | -9.11 M Decreased by -16.91% | Decreased by -894.50% Increased by +55.90% |